Differentiation potential of Mesenchymal Stem/Stromal cells is altered by Intrauterine Growth Restriction

Citation for published version:
Weatherall, E, Avilkina, V, Cortés Araya, Y, Dan-Jumbo, S, Stenhouse, C, Donadeu, X & Esteves, C 2020, 'Differentiation potential of Mesenchymal Stem/Stromal cells is altered by Intrauterine Growth Restriction', Frontiers in Veterinary Science. https://doi.org/10.3389/fvets.2020.558905

Digital Object Identifier (DOI):
10.3389/fvets.2020.558905

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Frontiers in Veterinary Science

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Differentiation Potential of Mesenchymal Stem/Stromal Cells Is Altered by Intrauterine Growth Restriction

Emma L. Weatherall 1*, Viktorija Avilkina 1, Yennifer Cortes-Araya 1, Susan Dan-Jumbo 1, Claire Stenhouse 1, Francesc X. Donadeu 1,2 and Cristina L. Esteves 1*

1 The Roslin Institute and The Royal (DICK) School of Veterinary Studies (R(D)SVS), The University of Edinburgh, Edinburgh, United Kingdom, 2 The Euan Macdonald Centre, The University of Edinburgh, Edinburgh, United Kingdom

Consistency in clinical outcomes is key to the success of therapeutic Mesenchymal Stem/Stromal cells (MSCs) in regenerative medicine. MSCs are used to treat both humans and companion animals (horses, dogs, and cats). The properties of MSC preparations can vary significantly with factors including tissue of origin, donor age or health status. We studied the effects of developmental programming associated with intrauterine growth restriction (IUGR) on MSC properties, particularly related to multipotency. IUGR results from inadequate uterine capacity and placental insufficiency of multifactorial origin. Both companion animals (horses, dogs, cats) and livestock (pigs, sheep, cattle) can be affected by IUGR resulting in decreased body size and other associated changes that can include, alterations in musculoskeletal development and composition, and increased adiposity. Therefore, we hypothesized that this dysregulation occurs at the level of MSCs, with the cells from IUGR animals being more prone to differentiate into adipocytes and less to other lineages such as chondrocytes and osteocytes compared to those obtained from normal animals. IUGR has consequences on health and performance in adult life and in the case of farm animals, on meat quality. In humans, IUGR is linked to increased risk of metabolic (type 2 diabetes) and other diseases (cardiovascular), later in life. Here, we studied porcine MSCs where IUGR occurs spontaneously, and shows features that recapitulate human IUGR. We compared the properties of adipose-derived MSCs from IUGR (IUGR-MSCs) and Normal (Normal-MSCs) new-born pig littermates. Both MSC types grew clonally and expressed typical MSC markers (CD105, CD90, CD44) at similar levels. Importantly, tri-lineage differentiation capacity was significantly altered by IUGR. IUGR-MSCs had higher adipogenic capacity than Normal-MSCs as evidenced by higher adipocyte content and expression of the adipogenic transcripts, PPARγ and FABP4 (P < 0.05). A similar trend was observed for fibrogenesis, where, upon differentiation, IUGR-MSCs expressed significantly higher levels of COL1A1 (P < 0.03) than Normal-MSCs. In contrast, chondrogenic and osteogenic potential were decreased in IUGR-MSCs as shown by a smaller chondrocyte pellet and osteocyte staining, and lower expression of SOX9.
therefore are considered as “Medicinal Signaling Cells” (Weatherall et al. IUGR-MSCs Differentiation Potential). Regenerative therapies both in humans (20–23) resulting in delayed fetal growth and small weight at birth often associated with placental insufficiency as a result of maternal advanced diabetes, anemia and high blood pressure, and obesity, and an increased risk of type 2 diabetes and cardiovascular disease in adulthood (26–28).

IUGR has been reported to affect cell growth and adipogenesis differentiation properties of stem cells (29, 30), which may underlie altered developmental phenotype and predisposition to later disease in IUGR individuals. However, the impact of IUGR on MSC properties is still unclear.

Pigs offer a relevant model to study IUGR. In pigs, IUGR occurs spontaneously, and recapitulates human IUGR features, including altered body development characterized by reduced musculoskeletal growth and a tendency to accumulate body fat post-nataly (31–33), as it is also observed in other models (16, 34). Using the IUGR pig model (16, 35, 36), and in order to assess the effect of developmental programming on MSCs, we compared the properties of MSCs obtained from IUGR and normal newborn pig littermates. Considering the IUGR phenotype, we hypothesized that IUGR impacts on MSCs properties by increasing adipogenesis and fibrogenesis and decreasing the ability of cell differentiation into other lineages such as osteogenesis and chondrogenesis.

Keywords: MSC - 51 (SCM), adipogenesis, osteogenesis, chondrogenesis, pig, IUGR, regenerative

INTRODUCTION

Mesenchymal Stem/Stromal cells (MSCs) are used in regenerative therapies both in humans (1) and in veterinary species (horses, dogs, and cats) (2–6). MSCs are typically obtained from bone marrow and adipose tissue, but other sources such as umbilical cord are also becoming more regularly investigated (7, 8). As defined by the International Society for Cellular Therapy (ISCT) (9), MSCs grow adherent to plastic and clonally, and express a group of surface markers, CD105, CD73, and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79α or CD19 and HLA-DR. In addition, MSCs are multipotent having the capacity of differentiating into cells of the mesenchymal lineage (adipocytes, osteocytes, and chondrocytes), and these features have been explored for regenerative therapeutic purposes. These cells produce trophic factors which are relevant to the repair processes in vivo, and therefore are considered as “Medicinal Signaling Cells” (10).

Different factors, such as donor (11) and age (12), can have considerable impact on MSC properties and clinical outcome, increasing the difficulty of MSC standardization, commercialization and therapeutic use. In addition, donor disease, such as diabetes and osteoarthritis (13, 14) can have a detrimental impact on the quality of MSC preparations from the stromal vascular fraction, which are heterogeneous cells obtained from extracts containing stem and other cells, such as those of endothelial and hematopoietic origin.

In IUGR, which is observed both in humans and veterinary species, the fetus fails to reach its full genetic growth potential (15) resulting in an increased risk of premature offspring death. This is the case of “runt” puppies, which may actually be preferred by some owners due to their appearance, but are at increased risk of presenting adverse developmental and metabolic features in adulthood (16, 17). Likewise, IUGR can affect equine health and performance in adulthood by impacting negatively on muscle and skeleton development and function, metabolism and pulmonary efficiency (18, 19).

In humans, IUGR occurs in about 10–40% pregnancies (20–23) resulting in delayed fetal growth and small weight at birth often associated with placental insufficiency as a result of maternal advanced diabetes, anemia and high blood pressure, malnutrition, multiple gestation of two or more fetuses, infection, alcohol consumption and use of recreation drugs (24, 25). Epidemiological data have shown a clear link between IUGR and obesity, and an increased risk of type 2 diabetes and cardiovascular disease in adulthood (26–28).

In conclusion, the regenerative potential of MSCs appears to be determined prenatally in IUGR and this should be taken into account when selecting cell donors in regenerative therapy programmes both in humans and companion animals.

MATERIALS AND METHODS

Samples

Subcutaneous adipose tissue samples were obtained immediately postmortem from three pairs of littermates Large White × Landrace, 1–7 days old, in accordance to the UK Home Office Animals (Scientific Procedures) Act 1986, schedule 1, by decapitation following administration of isoflurane and euthatal.

Normal and IUGR (birthweight below two standard deviations the average litter weight) mates were collected from each litter. Tissue samples were kept on ice in PBS with amphotericin B and 1% Penicillin and Streptomycin (P/S; Life Technologies-Thermo Fisher Scientific) until cell extraction <1 h after collection.

Cell Extraction and Culture

Adipose tissue was minced and digested in the presence of collagenase II (1 mg/ml Thermo Fisher Scientific), Bovine Serum Albumin (3.5%) and DNase (40 μg/ml Sigma-Aldrich) for 1 h at 37°C with gentle rotation at 100 rpm (37, 38). Collagenase activity was stopped with Dulbecco’s Modified Eagle Medium (DMEM; D5796; Sigma), 20% FBS (Thermo Fisher Scientific). After removing the lipid layer, the stromal vascular fraction was filtered through a 40 μm cut-off sieve. Cells were cultured initially in DMEM High Glucose supplemented with 20% FBS (Life Technologies-Thermo Fisher Scientific) and 50 μg/ml basic fibroblast growth factor (bFGF; ReproTech), and then, in the subsequent passages, bFGF was removed from the medium and FBS reduced to 10%.
Cell Growth Analyses
Doubling time was calculated using the formula:

\[
\text{Doubling Time} = \frac{\text{Time in culture} \times \log(2)}{\log(\text{Final number}) - \log(\text{Initial number})}
\]

Where “Initial” and “Final” numbers refer to number of cells at seeding and harvesting, respectively. To test the ability of cells to grow clonally, 250, 500, and 1,000 cells from each population at passage 3 were plated in 6-well plates, and cultured for 10 days. Cells were then fixed with paraformaldehyde (2%; 30 min) and washed with PBS P/S before staining with 1% Crystal violet in 100% Methanol.

Analyses of Cell Differentiation
Adipogenesis
To induce adipogenesis cells were seeded on collagen (0.2%) in 24-well plates (50,000 cells/well) and grown until confluence as previously described (5). Cells were kept for 5 days in differentiation medium consisting of DMEM supplemented with 7% Rabbit Serum (Gibco), 3% FBS, 1% P/S, 1 μM dexamethasone (Sigma-Aldrich), 10 μg/ml insulin (Sigma-Aldrich) and 0.5 mM 3-isobutyl-1-methylxanthine. This was followed by 7 days of cell culture in DMEM with 10% FBS, 1% P/S and 10 μg/ml insulin. Medium was changed every 2–3 days. In order to visualize lipid accumulation, differentiated adipocytes were stained with Oil red O (0.375% prepared in isopropanol) for 10 min and imaged in a Zeiss Axiovert 25 Inverted Phase microscope, and differences between the two types of cells were assessed visually.

Fibrogenesis
Fibrogenesis was induced when cells reached 80% confluence by using a medium consisting of DMEM High Glucose, supplemented with 0.5% FBS, 0.1 mM Ascorbic acid, 1% P/S, 0.1 mg/ml Dextran Sulfate Sodium Salt, and 2.5 ng/ml Transforming Growth Factor β (Sigma) for 3 and 6 days, as previously described (39). However, by day 6 of differentiation cells were detaching from the cell culture vessel and dying, and these samples were not analyzed. Collagen was detected by staining cell cultures with Picrosirus Red (0.3% prepared in glacial acetic acid in 50 mL MilliQ water) and micrographs were taken in a Zeiss Axiovert 25 Inverted Phase microscope and radius measured with Zen 2 software (Advanced Micro Devices) and statistical significance was defined as P < 0.05.

Osteogenesis
Osteogenic differentiation was induced when cells reached 90% confluence with DMEM high glucose and DMEM low glucose (50:50 v/v; Sigma-Aldrich), supplemented with 10% FBS, 100 nM dexamethasone (Sigma-Aldrich), 10 mM sodium β-glycerophosphate (Sigma-Aldrich) and 0.1 mM stabilized ascorbic acid (Sigma-Aldrich) (37). After 3 days, cells were switched to DMEM low glucose supplemented with 10% FBS, 100 nM dexamethasone, 10 mM sodium β-glycerophosphate and 0.1 mM stabilized ascorbic acid. Cells were cultured for 12 days and medium was changed every 3 days. At the end of the differentiation period cells were stained with Alizarin Red (2%; pH 4.2) for 2 h and imaged in a Zeiss Axiovert 25 Inverted Phase microscope using Zen 2 software (Advanced Micro Devices) and differences between the two types of cells were assessed visually.

Chondrogenesis
Chondrogenesis was induced by using the StemPro Chondrogenesis Differentiation Kit (A1007101, Thermofisher). Briefly, cells were seeded in micromasses (80,000 cells/each) and incubated for 2 h in a humidified chamber in the incubator before differentiation medium was added. After 28 days, the chondrogenic micromasses were either harvested into Trizol for gene expression measurements or fixed in paraformaldehyde (4%) for 45 min and directly stained overnight with Alcian Blue (1%; Sigma). Pellets were imaged in a Zeiss Axiovert 25 Inverted Phase microscope and radius measured with Zen 2 to calculate the spherical area (A = 4πr², where A is the area and r the radius).

Gene Expression Analysis
Gene expression analysis was performed in cells before and after differentiation. RNA was extracted using TRIzol reagent (Invitrogen), and 500 ng were reversed transcribed with Superscript III (Invitrogen). qPCR was performed using the SensiFAST SYBR Lo-ROX (BIO-94020; Bioline) in a Stratagene thermocycler with primers listed in Table 1. Relative transcript abundance was obtained using MX3005P software by extrapolating Ct values from a standard curve prepared from a sample pool, and TOP2B and RPL4 genes were used as housekeeping gene controls. Differentiation time-point data were normalized to values from undifferentiated cells (Day 0).

Statistical Analysis
Results were analyzed by Student’s t-test or Two-way ANOVA followed by Tukey’s post hoc test as appropriate, by using GraphPad Prism 8.2.1. Experiments were performed in triplicate and statistical significance was defined as P < 0.05.

| Gene         | Forward primer       | Reverse primer       |
|--------------|----------------------|----------------------|
| CD44         | CAGGTACGATTTCAATATCA | ACTGGGTTTTGTTTCTCTT  |
| CD90         | GACGACGCATATGAACTAC  | GTGAGCTCTGTGATAAGAG  |
| CD105        | ATACAAAGGGCTCCTGATT  | TGGATAGCTTTCTTTCTTT  |
| CTRP5        | CTGCCATGGCTGCTGCTG   | TGGAGCAGAGAGAGAGAG   |
| COL1A1       | TTCTAAGCGCGGCTGCTGC  | TGTGCTGCACTGCTCTTC  |
| ALP          | ATGACTGCTACGGGAAACAA | TGGCCTGGTCAATCTCT   |
| RUNX2        | CAAAGGCCAGGAGGAGAC   | AAACTCTAGCATGATCGG   |
| SOX9         | TCAAAGGGGAGACGGGAG   | TGGAGCAGAGAGAGAGAG   |
| RPL4         | AATTTGGAATTTAAGCTG   | GAACTCTAGCAATGATCGG |
| TOP2B        | AATTTGGAATTTAAGCTG   | GAACTCTAGCAATGATCGG |

*Primers designed in a previous study (41).
RESULTS

IUGR- and Normal-Cells Displayed Typical MSC Features
MSCs from both IUGR and Normal animals presented similar morphology in culture and exhibited clonal growth (Figures 1A,B). In addition, IUGR-MSCs grew faster than Normal-MSCs but only during the first 2 passages ($P = 0.001$; Figure 1C) after which both cell types showed the same rate of division. In addition, both IUGR- and Normal-MSCs expressed the classical MSC markers, CD44, CD90, and CD105 which levels were not statistically different (Figure 1D and Supplementary Table 1; $P = 0.8, 0.4, 0.9$, respectively), while the hematopoietic cell marker CD45 was not detected in either cell type.

IUGR-MSCs Showed Increased Adipogenesis and Fibrogenesis Compared to Normal-MSCs
Upon induction of adipogenesis, both MSC types produced mature adipocytes, as shown by staining of intracellular lipids with Oil Red O (Figure 2A). However, differentiation was more efficient for IUGR- than Normal-MSCs as evidenced by the expression of adipogenesis-associated genes, PPARγ and FABP4, a transcription factor and a fatty acid carrier protein, respectively ($P < 0.05$; Figures 2B,C). Likewise, fibrogenesis as evidenced by the Picrosirius Red collagen staining (Figure 3A), was more pronounced in IUGR-MSCs, as shown by higher expression of COL1A1, a major component of type I collagen ($P < 0.03$; Figure 3B), 3 days after the induction of differentiation of IUGR-compared to Normal-MSCs.

IUGR-MSCs Showed Attenuated Osteogenesis Compared to Normal-MSCs
Contrary to what was observed for adipogenesis and fibrogenesis, IUGR-MSCs had reduced osteogenic capacity compared to Normal-MSCs, as indicated by lower expression of RUNX2 and ALP (a transcription factor and a osteogenic marker, respectively; $P < 0.02$; Figures 4B,C) after 12 days of differentiation in IUGR-MSCs. Differentiated cells stained positively with Alizarin Red (Figure 4A) and both RUNX2 and ALP genes increased during differentiation of Normal-MSCs ($P < 0.04$), however, ALP ($P = 0.02$) but not RUNX2 ($P = 0.96$) increased during differentiation of IUGR-MSCs.

IUGR-MSCs Presented Decreased Chondrogenesis Compared to Normal-MSCs
Both Normal- and IUGR-MSCs differentiated into chondrocytic micromasses as evidenced by Alcian Blue staining (Figure 5A) and increased transcription factor SOX9 expression levels ($P < 0.05$). Similarly to osteogenic differentiation, chondrogenesis was more extensive in Normal- than in IUGR-MSCs as demonstrated by the larger micromasses ($P = 0.001$; Figures 5A,B) and higher expression levels of the transcription factor SOX9 ($P < 0.05$; Figure 5C) measured after 28 days of differentiation.

DISCUSSION
Dysregulated tissue development and a predisposition for later life disease in IUGR are thought to result from programming effects during fetal development. The implications of fetal programming on the properties of body stem cell populations and their potential for regenerative medicine are still unclear. The pig, a multiparous species, provides a well-established, preclinical model of cell-based tissue regeneration and engineering, gene therapy and xenotransplantation, most notably in relation...
FIGURE 2 | Adipogenic differentiation of IUGR- and Normal-MSCs. (A) Micrographs showing differentiated adipocytes of IUGR- and Normal-MSCs stained with Oil red O. Scale bars correspond to 100 µm of micrographs taken at 20×. mRNA levels, measured by qPCR, of (B) PPARγ and (C) FABP4 during adipogenic differentiation of IUGR- and Normal-MSCs. All results are shown as mean ± SEM; AU, arbitrary units. *P < 0.05, indicates differences between IUGR- and Normal-MSCs.

FIGURE 3 | Fibrogenesis of IUGR- and Normal-MSCs. (A) Micrographs presenting undifferentiated (Und) and differentiated (Diff) cells from IUGR- and Normal-MSCs, stained with Picrosirius Red collagen staining. Scale bars correspond to 100 µm of micrographs taken at 20×. (B) mRNA levels of COL1A1, measured by qPCR, in IUGR- and Normal-MSCs before (day 0) and after 3 days of induction of fibrogenesis. All results are shown as mean ± SEM; AU, arbitrary units. *P < 0.05, indicates differences between IUGR- and Normal-MSCs.

Increased in detriment of chondrogenesis and osteogenesis, as assessed by gene expression of appropriate markers and chemical stainings of differentiated cells (which were only visually evaluated). This indicates that stem cell programming during fetal development impacts negatively on the quality of MSCs by compromising their differentiation potential. These are important aspects that should be taken into consideration during selection of MSCs for regenerative therapy applications.

Porcine MSCs have been characterized (47, 48), and they display features, in terms of marker expression and multipotency, that are similar to those of companion animals and human MSCs (49). Here, we showed that, similar to Normal-MSCs, IUGR-MSCs displayed classical features of human and porcine MSCs (49–51) namely of CD marker expression, as defined by ISCT (9), and, except for a faster initial cell growth of Normal-MSCs, there were no differences between the two cell types. Others studies, using different IUGR models showed variable results regarding MSC growth; in the rat, food-restriction caused increased cell proliferation of bone marrow MSCs (29), whilst in the sheep, bone marrow MSC proliferation was reportedly reduced with poor maternal nutrition (30).

IUGR in humans (21, 28) and animals, namely pig (33, 52, 53), sheep (31) and rat (54), results in increased body adiposity and fibrosis (55, 56). In contrast, IUGR has a negative impact on bone (34, 57), cartilage (58) and skeletal muscle development (33, 59) as observed in horses (18, 19) and dogs.
Our results indicated an increased predisposition of IUGR-MSCs for adipogenesis and fibrogenesis which suggested that IUGR programmes the adult stem cell niche during fetal development, and this may underpin the increased accumulation of fat and fibrous tissue reported in IUGR individuals, later in life (61). This is likely to be a generalized body effect, i.e., not limited to adipose-derived stem cells as the same effect was observed by us in cells obtained from skeletal muscle (unpublished results) and in bone marrow IUGR-MSCs in other studies (29). In addition, we showed that IUGR MSCs had decreased osteogenic and chondrogenic capacities, in agreement with observations in different IUGR models in vivo (16). IUGR may also impact other MSC properties which were not part of the objectives of the present work, such as those related to angiogenesis and immunomodulation. A negative association between adipogenesis and osteogenesis in the body is also observed in other settings, such as aging, osteoporosis and obesity (62, 63). It is conceivable that in some instances these effects may be linked to IUGR, or at least, they are likely to be exacerbated in IUGR subjects with consequences for health, tissue repair and healing and, therefore, for the therapeutic efficacy of MSC preparations and this warrants further investigation in future projects.

In agreement to our hypothesis we show that MSC properties are developmentally programmed in IUGR resulting in an enhanced capacity to differentiate into adipogenic and fibrogenic lineages at the expense of the osteogenic and chondrogenic lineages, as we observed in
early passaged MSCs. This may underlie tissue development and inform on the development of therapies relevant to disease predisposition phenotypes observed during adulthood in IUGR individuals. Our results highlight important considerations when selecting MSC donors for regenerative medicine applications.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

Since the material used in the study was obtained post-mortem no licence is required following the guidelines of UK Home Office Animals 93 (Scientific Procedures) Act 1986.

**AUTHOR CONTRIBUTIONS**

EW, VA, YC-A, SD-J, and CS performed the experiments. EW, VA, and CE analyzed the data. CE and FD designed the project and wrote the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This research was supported by Strategic Grant funding from the Biotechnology and Biological Sciences Research Council (BBSRC) (BBS/E/D/10002071). YC-A and SD-J were supported by scholarships from CONICYT (Chile) and the University of Edinburgh, respectively.

**ACKNOWLEDGMENTS**

The authors would like to thank Ms. Marianne Farish and Mr. Peter Finnie from Bush Estate Farms, Scotland’s Rural College, for their help and skilled assistance.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fvets.2020.558905/full#supplementary-material

**REFERENCES**

1. Galipeau J, Sensebe L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. *Cell Stem Cell.* (2018) 22:824–33. doi: 10.1016/j.stem.2018.05.004
2. Fortier LA, Travis AJ. Stem cells in veterinary medicine. *Stem Cell Res Ther.* (2011) 2:9. doi: 10.1186/scrt50
3. Gugjoo MB, Amarpal, Chandra V, Wani MY, Dhama K, Sharma GT. *Mesenchymal stem cell research in veterinary medicine.* Curr Stem Cell Res Ther. (2018) 13:645–57. doi: 10.2174/1574888X1366618051707444
4. Lange-Consiglio A, Corradetti B, Bizzaro D, Magatti M, Ressl L, Tassan S, et al. Characterization and potential applications of progenitor-like cells isolated from horse amniotic membrane. *J Tissue Eng Regen Med.* (2012) 6:622–35. doi: 10.1002/term.465
5. Esteves CL, Sheldrake TA, Mesquita SP, Pesantez JJ, Menghini T, Dawson L, et al. Isolation and characterization of equine native MSC populations. *Stem Cell Res Ther.* (2017) 8:80. doi: 10.1186/s13287-017-0525-2
6. Esteves CL, Donadeu FX. Pericytes and their potential in regenerative medicine across species. *Cytotherapy.* (2017) 93:50–9. doi: 10.1002/cyt.a.23243
7. Li B-j, Li P-h, Huang R-h, Sun W-x, Wang H, Li Q-f, et al. Isolation, culture and identification of porcine skeletal muscle satellite cells. *Asian J Anim Sci.* (2015) 28:1171–7. doi: 10.5713/ajas.14.0848
8. Lovati AB, Corradetti B, Lange Consiglio A, Recordati C, Bonacina E, Bizzaro D, et al. Comparison of equine bone marrow-, umbilical cord matrix and amniotic fluid-derived progenitor cells. *Vet Res Commun.* (2011) 35:103–21. doi: 10.1007/s11266-010-9457-3
9. Dominici M, Blanc K, Mueller I. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy.* (2006) 8:315–7. doi: 10.1080/14653240600855905
10. Vagnozzi RJ, Maillet M, Sargent MA, Khalil H, Johansen AKZ, Schwanekamp JA, et al. An acute immune response underlies the benefit of cardiac stem cell therapy. *Nature.* (2020) 577:405–9. doi: 10.1038/s41586-019-1802-2
11. Kim M, Erickson IE, Huang AH, Garrity ST, Mauck RL, Steinberg DR. Donor variation and optimization of human mesenchymal stem cell chondrogenesis in hyaluronic acid. *Tissue Eng Part A.* (2018) 24:1693–703. doi: 10.1089/teng.tea.2017.0520
24. Cetin I, Mando C, Calabrese S. Maternal predictors of intrauterine growth restriction. *Clin Opin Clin Nutr Metab Care*. (2013) 16:310–9. doi: 10.1097/MCO.0b013e32835e8f9c

25. Moh W, Graham JM Jr, Wadhawan I, Sanchez-Lara PA. Extrinsic factors influencing fetal deformations and intrauterine growth restriction. *J Pregnancy*. (2012) 2012:750485. doi: 10.1155/2012/750485

26. Barker DJ. Adult consequences of fetal weight. *Clin Obstet Gynecol*. (2004) 49:270–83. doi: 10.1097/00001081-200606000-00009

27. Desai M, Ross MG. Fetal programming of adipose tissue: effects of intrauterine growth restriction and maternal obesity/high-fat diet. *Semin Reprod Med*. (2011) 29:237–45. doi: 10.1055/s-0031-1275517

28. Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. *Pediatr Res*. (1995) 38:733–9. doi: 10.1203/00006450-1995911000-00017

29. Gong M, Antony S, Sarkarui R, Liu J, Iacovino M, Rehan VK. Bone marrow mesenchymal stem cells of the intrauterine growth restricted rat offspring exhibit enhanced adipogenic phenotype. *Int J Obes*. (2016) 40:1768–75. doi: 10.1038/ijo.2016.157

30. Pillai SM, Sereda NH, Hoffman ML, Valley EV, Crenshaw TD, Park YK, et al. Effects of poor maternal nutrition during gestation on bone development and mesenchymal stem cell activity in offspring. *PLoS ONE*. (2016) 11:e0168382. doi: 10.1371/journal.pone.0168382

31. Greenwood PL, Bell AW. Consequences of intra-uterine growth retardation for postnatal growth, metabolism and pathophysiology. *Reprod Suppl.* (2003) 61:195–206. doi: 10.1530/bioexpress.5.015

32. Krueger R, Derno M, Goers S, Metzler-Zebeli BU, Nuernberg G, Martens K, et al. Higher body fatness in intrauterine growth retarded juvenile pigs is associated with lower fat and higher carbohydrate oxidation during ad libitum and restricted feeding. *Eur J Nutr*. (2014) 53:583–97. doi: 10.1007/s00394-013-0567-x

33. Rehfeldt C, Kuhn G. Consequences of birth weight for postnatal growth performance and carcass quality in pigs related to myogenesis. *J Anim Sci*. (2006) 84(Suppl.):E113–23. doi: 10.2527/2006.84.8supplE113x

34. Chen H, Miller S, Lane RH, Moyer-Miller JI. Intrauterine growth restriction decreases endochondral ossification and bone strength in female rats. *Am J Perinatol*. (2011) 30:261–6. doi: 10.1055/s-0032-1323588

35. Bauer R, Walter B, Hoppe A, Gaser E, Lampe V, Kauf E, et al. Body weight during ad libitum and restricted feeding. *Knee Surg Sports Traumatol Arthrosc*. (2015) 23:161–71. doi: 10.1007/s00167-014-3180-3

36. Poore KR, Fowden AL. The effects of birth weight and postnatal growth patterns on fat depth and plasma leptin concentrations in juvenile and adult pigs. *J Physiol*. (2004) 558:295–304. doi: 10.1111/j.1469-8137.2004.00319.x

37. Sena R, Baratta M, Mainardi GL, Renaville R, Giustina A, Quintavalla F, et al. IGF-I, IGFBP-2 and IGFBP-3 concentrations in umbilical cord plasma of normal and growth restricted newborn piglets. *Pediatr Res*. (1995) 38:733–9. doi: 10.1203/00006450-1995911000-00017

38. Faye DA, van den Akker F, Noort W, Chamauleau SA, Doehendans PA, Sluiter JP. Isolation of pig bone marrow-derived mesenchymal stem cells. *Methods Mol Biol*. (2016) 1416:225–32. doi: 10.1007/978-1-4939-3584-0_12

39. Noort WA, Oerlemans MI, Rozemuller H, Feyen D, Jaksani S, Stecher D, et al. Human versus porcine mesenchymal stromal cells: phenotype, differentiation potential, immunomodulation and cardiac improvement after transplantation. *J Cell Med*. (2012) 16:1827–39. doi: 10.1111/j.1582-4934.2011.01455.x

40. Hu C, Zhou N, Li J, Shi D, Cao H, Li J, et al. Porcine adipose-derived mesenchymal stem cells retain their stem cell characteristics and cell activities while enhancing the expression of liver-specific genes after acute liver failure. *Int J Mol Sci*. (2016) 17:62. doi: 10.3390/ijms17010062

41. Bharti D, Shivakumar SB, Subbarao RB, Rho GJ. Research advancements in adipogenic transcription factors in intracellular growth restriction. *Semin Cell Stem Cell*. (2016) 60:11–20. doi: 10.1016/j.semcemtre.2015.12.010

42. Delphingaro-Augusto V, Madad L, Chandra A, Simeonovic CJ, Dahlstrom JE, Nolan CJ. Iset inflammation, hemosiderosis, and fibrosis in intrabuterine growth-restricted and high-fat fed Sprague-Dawley rats. *Am J Physiol Growth*. (2018) 14:1844–56. doi: 10.1152/ajplin.2014.01248

43. Lim K, Lombardo P, Schneider-Kolsky M, Black MJ. Intrauterine growth restriction coupled with hyperglycemia: effects on cardiac structure in adult rats. *Pediatr Res*. (2012) 72:344–51. doi: 10.1080/12289022.2012.674552

44. Namgung R, Tsang RC, Specker BL, Sierra RL, Ho ML. Reduced serum osteocalcin and 1,25-dihydroxyvitamin D concentrations and low bone mineral content in small for gestational age infants: evidence of decreased bone formation rates. *J Pediatr*. (1993) 122:269–75. doi: 10.1016/S0022-3476(06)80132-0

45. Tie K, Tan Y, Deng Y, Li J, Ni Q, Magdalou J, et al. Prenatal nicotine exposure induces poor articular cartilage quality in female adult offspring fed a high-fat diet and the intraterine programming mechanisms. *Reprod Toxicol*. (2016) 66:11–20. doi: 10.1016/j.reprotox.2015.12.010

46. Boldin LD, Hay WW Jr. Impact of placental insufficiency on fetal skeletal muscle growth. *Mol Cell Endocrinol*. (2016) 435:69–77. doi: 10.1016/j.mce.2016.03.017

47. Milla H, Feugier A, Grillet A, Anne J, Gonnier M, Martin M, et al. Inadequate passive immune transfer in puppies: definition, risk factors and
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.